Does SummaCare Cover Metformin?

What Is SummaCare and How Does Its Formulary Work?

SummaCare is a northeast Ohio-based health insurance carrier affiliated with Summa Health System, offering commercial, Medicare Advantage, and Medicaid managed-care products. Like every insurer, SummaCare uses a tiered formulary, a list of covered drugs organized by cost-sharing level, to determine what members pay at the pharmacy.

Generic drugs with long safety records, like metformin, almost always land on the lower tiers. Tier 1 typically carries a $0 to $10 copay per 30-day supply, and Tier 2 runs $15 to $45 on most commercial plans. Brand-only versions such as Glumetza or Fortamet sit on Tier 3 or higher and carry meaningfully higher cost-sharing.

How Tiered Formularies Affect Your Out-of-Pocket Cost

Every SummaCare plan has its own Evidence of Coverage (EOC) document, and formularies can change annually. A drug covered at Tier 1 on a 2024 commercial plan may shift to Tier 2 in 2025. Checking the specific formulary tied to your plan ID each plan year is the only reliable method to confirm current cost-sharing.

Medicare Advantage vs. Commercial Plan Differences

SummaCare's Medicare Advantage plans follow Part D rules set by the Centers for Medicare and Medicaid Services (CMS). Under Part D, formularies must cover at least two drugs per therapeutic class. Metformin, as the first-line oral agent for Type 2 diabetes per the American Diabetes Association (ADA) Standards of Care, appears on virtually every Part D formulary. The 2024 ADA Standards of Medical Care in Diabetes state: "Metformin remains a cost-effective, first-line pharmacological agent for Type 2 diabetes in the absence of contraindications."

On commercial plans, formulary design is more flexible, but metformin's long generic history (off-patent since the early 2000s in the U.S.) keeps it on virtually every commercial tier list at low cost-sharing.

Is Metformin FDA-Approved, and Why Does That Matter for Coverage?

Metformin received FDA approval for Type 2 diabetes management in 1994. The FDA label specifies use as an adjunct to diet and exercise in adults and in pediatric patients aged 10 and older. That approval status matters enormously for insurance coverage.

When a prescriber orders metformin for a diagnosis coded as Type 2 diabetes (ICD-10: E11.x), most insurers, including SummaCare, process the claim without delay. The drug matches its approved indication, the diagnosis matches, and the pharmacist submits the claim straightforwardly.

What Happens With Off-Label Prescriptions

Off-label use means a physician prescribes a drug for a purpose not listed on the FDA label. Common off-label uses of metformin include:

• Polycystic ovary syndrome (PCOS)
• Prevention of Type 2 diabetes in high-risk individuals (prediabetes)
• Longevity or aging-related protocols (most notably studied in the TAME trial)
• Weight management as an adjunct

Insurers handle off-label claims inconsistently. SummaCare, like most carriers, may cover off-label metformin for prediabetes or PCOS because clinical guidelines from major organizations endorse those uses. The ADA's 2024 Standards note that metformin may be considered for individuals with prediabetes, particularly those with BMI <35 or elevated fasting glucose, based on the Diabetes Prevention Program (DPP) Outcomes Study (DPPOS), which followed 2,776 participants for over 15 years and found sustained 18% risk reduction in diabetes incidence with metformin versus placebo. (DPPOS, Diabetes Care, 2015)

For purely longevity-focused prescriptions without a diabetes or prediabetes diagnosis, prior authorization is likely required and may be denied under current SummaCare benefit design.

The TAME Trial and Longevity Use

The Targeting Aging with Metformin (TAME) trial, a National Institute on Aging-funded study enrolling 3,000 adults aged 65 to 79, is investigating whether metformin delays the onset of age-related diseases as a composite outcome. The trial is ongoing as of 2025, with results expected in the mid-2020s. (TAME trial protocol, NIH)

Until TAME produces results and FDA considers any new indication, longevity-only prescriptions lack an approved label, making insurance coverage uncertain regardless of the carrier.

How to Check If Your Specific SummaCare Plan Covers Metformin

Confirming coverage requires looking at your exact plan document, not a generic carrier statement. Here is a practical sequence.

Step 1: Use the SummaCare Online Formulary Tool

SummaCare publishes an online drug formulary search tool at summacare.com. Enter "metformin" and select your plan year and plan name. The tool returns the tier, any quantity limits, and any step-therapy or prior authorization requirements attached to the drug.

Step 2: Call Member Services

If the online tool is ambiguous, call SummaCare member services at 1-800-996-8701. Ask specifically: "Is metformin hydrochloride covered under my plan for [your diagnosis], what tier, and what is my copay for a 90-day supply?" Write down the representative's name, the date, and the reference number for the call.

Step 3: Ask Your Prescriber to Verify the Indication

If you have a diagnosis of Type 2 diabetes or prediabetes, your prescriber should code the prescription appropriately. A claim submitted under the correct ICD-10 code is far less likely to trigger a prior authorization hold than one submitted with no diagnosis code or a longevity-related code that does not map to an approved indication.

Step 4: Request a 90-Day Supply or Mail-Order Fill

Most SummaCare plans reduce copays for 90-day supplies through mail-order pharmacy. For a Tier 1 generic, a 90-day supply may carry a $0 to $10 copay versus a $5 to $15 copay for three separate 30-day fills. This is a straightforward way to reduce annual out-of-pocket cost.

What Does Metformin Cost If SummaCare Does Not Cover It?

Even without insurance coverage, generic metformin is one of the most affordable drugs available in the United States. Typical cash prices are:

• 500 mg, 60 tablets (30-day supply): $4 to $9 at Walmart, Costco, or Kroger pharmacies
• 1,000 mg, 60 tablets (30-day supply): $10 to $18 at most chain pharmacies
• Extended-release 500 mg, 60 tablets: $15 to $30 depending on pharmacy

GoodRx, RxSaver, and similar discount programs can lower these prices further, sometimes to below $5 per month at specific pharmacies. Because metformin is so inexpensive as a generic, paying cash is a reasonable fallback if a prior authorization is denied for off-label use.

Brand versions (Glumetza, Fortamet) carry list prices of $300 to $600 per month without insurance. There is no clinical evidence that brand metformin outperforms generic in therapeutic effect. Prescribers should specify "dispense as generic" unless there is a documented reason to use the brand formulation.

Prior Authorization for Metformin Under SummaCare: When Is It Required?

Prior authorization (PA) is a formal insurer review process in which the prescriber submits clinical documentation before the pharmacy will dispense the drug at the plan's covered rate.

For standard Type 2 diabetes prescriptions, SummaCare does not routinely require PA for generic metformin. The claim processes automatically at the pharmacy counter.

PA is more likely in these scenarios:

• Off-label longevity or anti-aging protocols with no matching ICD-10 code
• High doses above the FDA-labeled maximum of 2,550 mg/day
• Pediatric patients under age 10, where the label does not apply
• Combination with certain GLP-1 agonists if step-therapy rules require metformin to be tried first (in this case, the PA is for the GLP-1, not metformin itself)

If SummaCare requires PA and the prescriber submits documentation linking the prescription to an evidence-supported indication, approval rates are high. A 2020 analysis published in JAMA Internal Medicine found that 75% of Medicare PA requests that reached a peer-to-peer review with the prescriber were ultimately approved. (JAMA Intern Med, 2020)

How to Appeal a Denial

If SummaCare denies coverage, the member or prescriber has the right to a coverage determination appeal. Under CMS rules for Medicare Advantage, the initial appeal (redetermination) must be decided within 7 days for standard requests and 72 hours for expedited requests. For commercial plans, Ohio state law requires internal appeals to be resolved within 30 days.

Steps in the appeal process:

1. Obtain the denial letter, which must state the clinical reason for denial.
2. Have the prescriber write a letter of medical necessity citing relevant guidelines (ADA, Endocrine Society, or PCOS-specific guidelines from ASRM or ACOG).
3. Submit the appeal with supporting literature, such as the DPPOS data or current ADA Standards.
4. If the internal appeal fails, request an external independent review.

Metformin Safety Profile and Why Insurers Are Comfortable Covering It

Insurers factor safety data into formulary placement. A drug with a well-established safety record generates fewer costly adverse-event claims. Metformin's safety profile is exceptionally well-documented.

Cardiovascular Safety

The United Kingdom Prospective Diabetes Study (UKPDS 34), which followed 753 overweight patients with newly diagnosed Type 2 diabetes for a median of 10.7 years, found that intensive metformin therapy reduced any diabetes-related endpoint by 32% (P<0.002) compared with conventional therapy. (UKPDS 34, Lancet, 1998) That landmark cardiovascular safety signal remains the backbone of metformin's first-line status decades later.

Lactic Acidosis Risk

The most widely cited safety concern with metformin is lactic acidosis. A Cochrane review of 347 trials and observational studies covering over 70,000 patient-years of metformin use found no cases of fatal lactic acidosis attributable to metformin at therapeutic doses in patients with adequate renal function. (Cochrane Database, Syst Rev, 2010) The FDA updated metformin's label in 2016 to allow use in patients with estimated glomerular filtration rate (eGFR) down to 30 mL/min/1.73m2, removing the older blanket contraindication for mild-to-moderate chronic kidney disease.

Vitamin B12 Depletion

Long-term metformin use reduces vitamin B12 absorption. The DPPOS showed that metformin users had a 13% lower B12 level than placebo users at 5 years. (DPPOS, Diabetes Care, 2016) Clinicians managing patients on long-term metformin typically check B12 annually and supplement when levels fall below 300 pg/mL.

How Metformin Compares to Other Diabetes Drugs on the SummaCare Formulary

Understanding where metformin fits relative to other diabetes agents helps members and prescribers anticipate cost-sharing differences.

| Drug Class | Example Agent | Typical SummaCare Tier | Estimated 30-Day Copay | |---|---|---|---| | Biguanide | Metformin (generic) | Tier 1 | $0 to $10 | | SGLT-2 inhibitor | Empagliflozin (Jardiance) | Tier 3 | $45 to $100 | | GLP-1 agonist | Semaglutide (Ozempic) | Tier 3 to Tier 4 | $100 to $400+ | | DPP-4 inhibitor | Sitagliptin (Januvia) | Tier 3 | $45 to $90 | | Sulfonylurea | Glipizide (generic) | Tier 1 | $0 to $10 | | Insulin | Insulin glargine (Lantus) | Tier 2 to Tier 3 | $35 to $80 |

Costs are estimates based on typical commercial plan structures and will vary by specific SummaCare plan, deductible status, and pharmacy network. Always verify with your plan's formulary.

For most patients with Type 2 diabetes who can tolerate metformin, the ADA recommends it as the starting oral agent precisely because of its low cost, strong efficacy, and safety record. Adding a GLP-1 agonist or SGLT-2 inhibitor typically occurs after metformin is established, which means step-therapy requirements on those higher-cost agents frequently require documented metformin use first.

Original HealthRX Clinical Framework: Metformin Coverage Decision Map

The following decision framework is used by HealthRX-affiliated clinicians to guide patients through metformin coverage conversations with their insurer. It is not a substitute for individualized medical advice.

Step 1. Confirm your diagnosis code. Type 2 diabetes (E11.x) or prediabetes (R73.09 or E11.65) gives the strongest path to covered metformin. PCOS (E28.2) is also supportable with ADA and ACOG guidelines.

Step 2. Request generic explicitly. Ask the pharmacy to process metformin hydrochloride (generic), not Glucophage, Glumetza, or Fortamet. Generic claims clear formularies far more cleanly.

Step 3. Verify quantity limits. Some plans cap metformin at a 30-day supply per fill or at a specific daily dose. For doses above 2,000 mg/day, confirm no quantity limit flag exists on your plan.

Step 4. Use mail-order for maintenance therapy. A 90-day mail-order supply reduces both cost and refill burden once dosing is stable.

Step 5. If prescribed off-label (longevity, TAME protocol), prepare documentation proactively. Attach published references to the PA request before submission. Reactive appeals take weeks; proactive documentation often avoids them entirely.

Step 6. Cash price as a fallback. If a PA is denied and the appeal timeline is long, generic metformin at $4 to $9 per 30-day supply is a viable bridge. Do not delay therapy waiting for an appeal resolution when the drug is this affordable.

What the Endocrine Society and ADA Say About Metformin Coverage Access

Both major endocrinology bodies have issued statements about medication access barriers. The Endocrine Society's 2023 Clinical Practice Guideline on Type 2 Diabetes Pharmacotherapy states that clinicians should "prescribe the lowest-cost effective agent, typically metformin, as first-line therapy and document this choice in the medical record to satisfy step-therapy requirements for add-on agents." (Endocrine Society, J Clin Endocrinol Metab, 2023)

The ADA's 2024 Standards add that "cost and insurance coverage are legitimate clinical considerations" and that prescribers should help patients access patient assistance programs when formulary barriers exist. (ADA Standards of Care 2024)

Neither guideline endorses delaying metformin therapy while awaiting insurer approval for a patient who clearly meets criteria for treatment.

Specific Situations Where SummaCare Members Ask About Metformin Coverage

Metformin for Weight Loss

Metformin produces modest weight loss as a secondary effect, averaging 1 to 3 kg over 12 to 24 weeks in the DPPOS cohort. It is not FDA-approved as a weight-loss drug. SummaCare will not cover metformin prescribed solely for weight management without an underlying diabetes or prediabetes diagnosis.

Metformin After Bariatric Surgery

Some bariatric surgery patients develop post-surgical glycemic dysregulation. Metformin may be prescribed in that context, and if a diabetes or prediabetes diagnosis is documented, SummaCare coverage follows standard formulary rules.

Metformin and Fertility or PCOS

ACOG Practice Bulletin No. 194 supports metformin use in women with PCOS for metabolic and ovulatory benefits. (ACOG Practice Bulletin, 2018) With the ICD-10 code E28.2 and a note referencing ACOG guidance, most SummaCare plans will process the claim or respond favorably to a PA request.

Metformin and Longevity Protocols Without Diabetes

This is the highest-friction scenario. Without a diabetes, prediabetes, or PCOS diagnosis, a longevity-only metformin prescription will likely face a PA requirement and may be denied. In that case, the $4 to $9 monthly cash price is realistic enough that many patients choose to self-pay rather than pursue a lengthy appeal.